Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871693 | 0.91 | GPR119 (0.43) | PIK3CAPRKDCKDM4EPKMGPR119 | |
| SCHEMBL7868718 | 0.91 | PIK3CA (0.46) | PIK3CAPRKDCKDM4EPKMGPR119 | |
| SCHEMBL7863517 | 0.91 | GPR119 (0.46) | PIK3CAPRKDCKDM4EPKMGPR119 | |
| SCHEMBL7868708 | 0.83 | GPR119 (0.43) | PIK3CAPRKDCKDM4EPKMGPR119 | |
| SCHEMBL7863458 | 0.78 | FPR2 (0.43) | PIK3CAPRKDCKDM4EPKMGPR119 | |
| SCHEMBL948301 | 0.74 | GPR119 (0.48) | KDM4EGPR119HPGDSTP53 | |
| SCHEMBL7871606 | 0.74 | GPR119 (0.45) | KDM4EPKMGPR119FAAH | |
| SCHEMBL8712463 | 0.74 | GPR119 (0.43) | KDM4EPKMGPR119FAAH | |
| SCHEMBL8713112 | 0.72 | GPR119 (0.45) | KDM4EPKMGPR119FAAH | |
| SCHEMBL7863430 | 0.72 | GPR119 (0.46) | KDM4EPKMGPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0826686-A2 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | PIK3CA 1040/4885PRKDC 2942/4885KDM4E 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.